Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study

BACKGROUND: Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response. To optimize Adefovir therapy in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive, we studied the ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hui, Geng, Da Ying, Shen, Fei, Zhang, Jing Yao, Lu, Bing, Ma, Li Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205069/
https://www.ncbi.nlm.nih.gov/pubmed/21936898
http://dx.doi.org/10.1186/1743-422X-8-444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205069/
https://www.ncbi.nlm.nih.gov/pubmed/21936898
http://dx.doi.org/10.1186/1743-422X-8-444

Ejemplares similares